Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2509)

VOLUNTARY ANNOUNCEMENT
EXCLUSIVE LICENSE AGREEMENT WITH CALDERA THERAPEUTICS FOR A PRECLINICAL BISPECIFIC ANTIBODY PROGRAM TARGETING TL1A AND IL-17

This announcement is made by Qyuns Therapeutics Co., Ltd. (the "**Company**") on a voluntary basis to inform its shareholders and potential investors of an update on the business developments of the Company.

The board of directors of the Company (the "**Board**") is pleased to announce that on November 5, 2026, the Company and Caldera Therapeutics, Inc. ("**Caldera Therapeutics**") have entered into an out-license agreement (the "**License Agreement**") covering a preclinical-stage bispecific antibody program targeting TL1A and IL-17, specifically IL-17A and IL-17A/F (the "**Licensed Program**").

Subject to terms and conditions of the License Agreement, Caldera Therapeutics is granted an exclusive, royalty-bearing, transferable, sublicensable right to research, develop, register, manufacture and commercialize product candidates arising from the Licensed Program worldwide. In return, the Company or its designated affiliate(s) (collectively, the "**Group**") will be entitled to receive a one-time, non-refundable, and non-creditable upfront payment of US$30 million. The Group may also receive additional payments of up to US$750 million, subject to the achievement of certain clinical development, regulatory and commercial milestones. The Group will also be entitled to receive tiered royalties on net sales of products arising from the Licensed Program during a specified time period after the first commercial sale.

ABOUT THE LICENSED PROGRAM

The Licensed Program comprises preclinical stage bispecific antibodies that are designed to inhibit TL1A and IL-17, two therapeutically relevant targets implicated in immune-mediated diseases.

ABOUT CALDERA THERAPEUTICS

Caldera Therapeutics is a clinical stage company developing QX030N/CLD-423, a bispecific antibody in Phase 1 clinical development for the treatment of inflammatory bowel disease (IBD) and other immune-mediated diseases. QX030N/CLD-423 is designed to simultaneously inhibit two inflammatory pathways: IL-23p19, which is clinically validated by multiple FDA-approved therapies, and TL1A, which is an emerging target supported by human genetics, disease biology, and positive clinical results in multiple IBD clinical trials. Caldera Therapeutics has assembled a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building companies through to successful exits.

Caldera Therapeutics is currently investigating QX030N/CLD-423 in Phase 1a healthy volunteer clinical trials, and, based on interim data generated to date, plans to initiate Phase 2 clinical trials in ulcerative colitis and Crohn's disease in early 2027. For details, please refer to www.calderatx.com.

To the best knowledge and belief of the Company, the ultimate beneficial owners of Caldera Therapeutics and its shareholders are not connected persons (as defined in the Listing Rules) of the Company. The transactions contemplated under the License Agreement do not constitute any notifiable transaction or connected transaction of the Company which are subject to announcement requirements under the Listing Rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, November 5, 2026

As at the date of this announcement, the Board of the Company comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Wu Zhiqiang as non-executive Director, and Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun as independent non-executive Directors.